• No Black Box Warning
  • No oral sodium phosphate
  • No reports of acute phosphate nephropathy
  • The ONLY prep approved with 2 liters & 1 bisacodyl tablet
  • Lowest volume phosphate-free lavage1,2

References: 1. HalfLytely® and Bisacodyl Tablet Bowel Prep Kit [package insert]. Braintree, MA: Braintree Laboratories, Inc; 2010.
2. See package inserts: GoLYTELY® (PEG-3350 and Electrolytes for Oral Solution), 2001; NuLYTELY® (PEG-3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution), 2008. Braintree MA: Braintree Laboratories, Inc.; MoviPrep® (PEG-3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), 2006. Morrisville, NC: Salix Pharmaceuticals, Inc.

HalfLytely® and Bisacodyl Tablet Bowel Prep Kit is a combination of PEG-3350, an osmotic laxative and bisacodyl, a stimulant laxative, indicated for cleansing of the colon as a preparation for colonoscopy in adults. Most common adverse reactions (>3%) are overall discomfort, abdominal fullness, abdominal cramping, nausea, and vomiting. There have been reports of ischemic colitis in patients with use of HalfLytely and 10 mg or 20 mg Bisacodyl Tablets Bowel Prep Kit. Use is contraindicated in the following conditions: gastrointestinal (GI) obstruction, bowel perforation, toxic colitis and toxic megacolon, gastric retention, ileus. Use caution when prescribing for patients with a history of seizures, arrhythmias, impaired gag reflex, regurgitation or aspiration, severe active ulcerative colitis, impaired renal function or patients taking medications that may affect renal function or electrolytes. Patients with impaired water handling who experience severe vomiting should be closely monitored including measurement of electrolytes. Advise all patients to hydrate adequately before, during, and after use.

Click here for full Prescribing Information and Medication Guide

Braintree Laboratories Code of Conduct
Braintree Laboratories California Health and Safety Code Statement

Copyright 2014 Braintree Laboratories, Inc.